Recruiting

Observational Study

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT02363595

Conditions

Papillary Microcarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic?

Therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.

Conditions

Papillary Microcarcinoma

Study ID

NCT02363595

Start date

Dec 31, 2014

Status verified date

Mar, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Biopsy proven papillary thyroid cancer (or suspicious for papillary thyroid cancer) confirmed by MSKCC cytopathologist.
  • Being followed with active surveillance at MSKCC
  • Biopsied index nodule less than or equal to 2 cm in maximum dimension
  • Thyroid and neck US performed and interpreted by a MSKCC radiologist within 6 months prior to study entry.

Exclusion Criteria:

  • Biopsied index nodule greater than 2 cm in any dimension
  • Age less than 18 yrs old

Study Design

Enrollment

750 participants

Anticipated

Interventions and Outcome Measures

Arms

Papillary Microcarcinoma

This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up

Primary outcome measure

  • estimate the disease progression rate [ Time Frame: 4 years ]

Central Contacts and Locations

Central contacts

Robert Tuttle, MD

646-888-2716

Michael Berger, PhD

646-888-3386

Locations

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 10065

Contacts

Robert Tuttle, MD

646-888-2716

Michael Berger, PhD

646-888-3386

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Mar 12, 2026

Last verified

Mar, 2026

Keywords

  • Genomic Predictors
  • 14-277

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-03-12.